BACKGROUND Insulin injection is the basic daily drug treatment for diabetic patients.AIM To evaluate the comparative impacts of continuous subcutaneous insulin infusion(CSII).METHODS Based on the treatment modality re...BACKGROUND Insulin injection is the basic daily drug treatment for diabetic patients.AIM To evaluate the comparative impacts of continuous subcutaneous insulin infusion(CSII).METHODS Based on the treatment modality received,the patients were allocated into two cohorts:The CSII group and the multiple daily injections(MDI)group,with each cohort comprising 210 patients.Comparative assessments were made regarding serum levels of serum-secreted frizzled-related protein 5,homocysteine,and C1q/TNF-related protein 9.Furthermore,outcomes such as fasting plasma glucose,2-hour postprandial glucose levels,pain assessment scores,and the incidence of complications were evaluated post-treatment.RESULTS The CSII group displayed notably lower fasting plasma glucose and 2-h postprandial glucose levels in comparison to the MDI group(P<0.05).Subsequent analysis post-treatment unveiled a significantly higher percentage of patients reporting no pain in the CSII group(60.00%)in contrast to the MDI group(36.19%)(P<0.05).Additionally,the CSII group exhibited a markedly reduced occurrence of fetal distress and premature rupture of membranes compared to the MDI group(P<0.05).However,there were no significant variances observed in other pregnancy outcomes between the two groups(P>0.05).A statistical analysis revealed a significant difference in the incidence of complications between the groups(χ^(2)=11.631,P=0.001).CONCLUSION The utilization of CSII via an insulin pump,as opposed to MDI,can significantly enhance the management of insulin administration in patients with GDM by diversifying the sites of insulin delivery.This approach not only promotes optimal glycemic control but also regulates metabolic factors linked to blood sugar,reducing the likelihood of adverse pregnancy outcomes and complications.The clinical relevance and importance of CSII in GDM management highlight its wide-ranging clinical usefulness.展开更多
目的探究胰岛素泵长期持续皮下胰岛素输注(CSII)治疗儿童1型糖尿病(T1DM)效果的影响因素。方法选取2021年1月至2022年12月在泉州市妇幼保健院·儿童医院接受CSII治疗的130例T1DM患儿作为研究对象,依据病历系统记录6个月后的空腹血糖...目的探究胰岛素泵长期持续皮下胰岛素输注(CSII)治疗儿童1型糖尿病(T1DM)效果的影响因素。方法选取2021年1月至2022年12月在泉州市妇幼保健院·儿童医院接受CSII治疗的130例T1DM患儿作为研究对象,依据病历系统记录6个月后的空腹血糖(FPG)、餐后2 h血糖(2 h PBG)及糖化血红蛋白(HbA1c)达标情况分为对照组(达标组,100例)、观察组(未达标组,30例),收集比较患儿相关资料,使用多因素logistic回归分析,分析胰岛素泵长期CSII治疗儿童T1DM效果的影响因素。结果两组患儿父母文化程度、家庭月收入、服药情况、胰岛素β细胞分泌指数(Homa-β)、胰岛素抵抗指数(Homa-IR)比较,差异有统计学意义(P<0.05)。多因素logistic回归分析结果显示,父母文化程度(β=1.159,OR=3.188,95%CI:1.372~7.403)、家庭月收入(β=1.286,OR=3.619,95%CI:1.544~8.480)、服药情况(β=1.168,OR=1.632,95%CI:1.017~3.711)为CISS对T1DM患儿治疗效果的危险因素(OR>1,P<0.05),Homa-β(β=-2.383,OR=0.092,95%CI:0.015~0.552)、Homa-IR(β=-3.402,OR=0.033,95%CI:0.003~0.387)为CSII对T1DM患儿治疗效果的保护因素(OR<1,P<0.05)。结论T1DM患儿长期CSII疗效的影响因素包含父母文化程度、家庭月收入、服药情况、Homa-β、Homa-IR,临床应对以上因素保持关注。展开更多
AIM:To evaluate metabolic control and health-related quality of life(HRQOL)in a type 1 diabetes mellitus(T1DM)population.METHODS:As part of a prospective cohort study,283T1DM patients treated with various insulin trea...AIM:To evaluate metabolic control and health-related quality of life(HRQOL)in a type 1 diabetes mellitus(T1DM)population.METHODS:As part of a prospective cohort study,283T1DM patients treated with various insulin treatment modalities including multiple daily injections(MDI)and continuous subcutaneous insulin infusion(CSII)were examined annually.HRQOL was measured using the SF-36 and EuroQol questionnaires.Data regarding HRQOL,glycaemic and metabolic control from baseline and follow-up measures in 2002 and 2010 were analysed.Linear mixed models were used to calculate estimated values and differences between the three moments in time and the three treatment modalities.RESULTS:Significant changes[meanΔ(95%CI)]in body mass index[2.4 kg/m2(1.0,3.8)],systolic blood pressure[-6.4 mmHg(-11.4,-1.3)]and EuroQol-VAS[-7.3(-11.4,-3.3)]were observed over time.In 2010,168 patients were lost to follow-up.Regarding mode of therapy,52 patients remained on MDI,28 remained on CSII,and 33 patients switched from MDI to CSII during follow-up.Among patients on MDI,HRQOL decreased significantly over time:mental component summary[-9.8(-16.3,-3.2)],physical component summary[-8.6(-15.3,-1.8)]and EuroQol-VAS[-8.1(-14.0,-2.3)],P<0.05 for all.For patients using CSII,the EuroQol-VAS decreased[-9.6(-17.5,-1.7)].None of the changes over time in HRQOL differed significantly with the changes over time within the other treatment groups.CONCLUSION:No differences with respect to metabolic and HRQOL parameters between the various insulin treatment modalities were observed after 15 years of follow-up in T1DM patients.展开更多
文摘BACKGROUND Insulin injection is the basic daily drug treatment for diabetic patients.AIM To evaluate the comparative impacts of continuous subcutaneous insulin infusion(CSII).METHODS Based on the treatment modality received,the patients were allocated into two cohorts:The CSII group and the multiple daily injections(MDI)group,with each cohort comprising 210 patients.Comparative assessments were made regarding serum levels of serum-secreted frizzled-related protein 5,homocysteine,and C1q/TNF-related protein 9.Furthermore,outcomes such as fasting plasma glucose,2-hour postprandial glucose levels,pain assessment scores,and the incidence of complications were evaluated post-treatment.RESULTS The CSII group displayed notably lower fasting plasma glucose and 2-h postprandial glucose levels in comparison to the MDI group(P<0.05).Subsequent analysis post-treatment unveiled a significantly higher percentage of patients reporting no pain in the CSII group(60.00%)in contrast to the MDI group(36.19%)(P<0.05).Additionally,the CSII group exhibited a markedly reduced occurrence of fetal distress and premature rupture of membranes compared to the MDI group(P<0.05).However,there were no significant variances observed in other pregnancy outcomes between the two groups(P>0.05).A statistical analysis revealed a significant difference in the incidence of complications between the groups(χ^(2)=11.631,P=0.001).CONCLUSION The utilization of CSII via an insulin pump,as opposed to MDI,can significantly enhance the management of insulin administration in patients with GDM by diversifying the sites of insulin delivery.This approach not only promotes optimal glycemic control but also regulates metabolic factors linked to blood sugar,reducing the likelihood of adverse pregnancy outcomes and complications.The clinical relevance and importance of CSII in GDM management highlight its wide-ranging clinical usefulness.
文摘目的探究胰岛素泵长期持续皮下胰岛素输注(CSII)治疗儿童1型糖尿病(T1DM)效果的影响因素。方法选取2021年1月至2022年12月在泉州市妇幼保健院·儿童医院接受CSII治疗的130例T1DM患儿作为研究对象,依据病历系统记录6个月后的空腹血糖(FPG)、餐后2 h血糖(2 h PBG)及糖化血红蛋白(HbA1c)达标情况分为对照组(达标组,100例)、观察组(未达标组,30例),收集比较患儿相关资料,使用多因素logistic回归分析,分析胰岛素泵长期CSII治疗儿童T1DM效果的影响因素。结果两组患儿父母文化程度、家庭月收入、服药情况、胰岛素β细胞分泌指数(Homa-β)、胰岛素抵抗指数(Homa-IR)比较,差异有统计学意义(P<0.05)。多因素logistic回归分析结果显示,父母文化程度(β=1.159,OR=3.188,95%CI:1.372~7.403)、家庭月收入(β=1.286,OR=3.619,95%CI:1.544~8.480)、服药情况(β=1.168,OR=1.632,95%CI:1.017~3.711)为CISS对T1DM患儿治疗效果的危险因素(OR>1,P<0.05),Homa-β(β=-2.383,OR=0.092,95%CI:0.015~0.552)、Homa-IR(β=-3.402,OR=0.033,95%CI:0.003~0.387)为CSII对T1DM患儿治疗效果的保护因素(OR<1,P<0.05)。结论T1DM患儿长期CSII疗效的影响因素包含父母文化程度、家庭月收入、服药情况、Homa-β、Homa-IR,临床应对以上因素保持关注。
文摘AIM:To evaluate metabolic control and health-related quality of life(HRQOL)in a type 1 diabetes mellitus(T1DM)population.METHODS:As part of a prospective cohort study,283T1DM patients treated with various insulin treatment modalities including multiple daily injections(MDI)and continuous subcutaneous insulin infusion(CSII)were examined annually.HRQOL was measured using the SF-36 and EuroQol questionnaires.Data regarding HRQOL,glycaemic and metabolic control from baseline and follow-up measures in 2002 and 2010 were analysed.Linear mixed models were used to calculate estimated values and differences between the three moments in time and the three treatment modalities.RESULTS:Significant changes[meanΔ(95%CI)]in body mass index[2.4 kg/m2(1.0,3.8)],systolic blood pressure[-6.4 mmHg(-11.4,-1.3)]and EuroQol-VAS[-7.3(-11.4,-3.3)]were observed over time.In 2010,168 patients were lost to follow-up.Regarding mode of therapy,52 patients remained on MDI,28 remained on CSII,and 33 patients switched from MDI to CSII during follow-up.Among patients on MDI,HRQOL decreased significantly over time:mental component summary[-9.8(-16.3,-3.2)],physical component summary[-8.6(-15.3,-1.8)]and EuroQol-VAS[-8.1(-14.0,-2.3)],P<0.05 for all.For patients using CSII,the EuroQol-VAS decreased[-9.6(-17.5,-1.7)].None of the changes over time in HRQOL differed significantly with the changes over time within the other treatment groups.CONCLUSION:No differences with respect to metabolic and HRQOL parameters between the various insulin treatment modalities were observed after 15 years of follow-up in T1DM patients.
